FDA
-
-
-
-
-
-
-
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
-
-
-
-
-
-
-
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
-
-
-
-
-
-
-
Tenaya Therapeutics reports interim data from gene therapy trial
-
-
-
-
-
-
-
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
-
-
-
-
-
-
-
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
-
-
-
-
-
-
-
Tenaya Therapeutics (TNYA) Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
-
-
-
-
-
-
-
Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
-
335,219 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


